/https://specials-images.forbesimg.com/imageserve/5e74a6d710380d0006bdb0ec/0x0.jpg "Spotify’s 25 Most Streamed Game Songs: Smash Hits, Snubs, and Surprises")
Published on:
Pfizer / BioNTech vaccines were first packaged on French soil on Wednesday in a measure hailed by President Emmanuel Macron as an important step as the country seeks to step up its vaccination campaign.
French pharmaceutical outsourcing company Delpharm began packaging vaccines in vials on Wednesday for delivery to distribution centers.
“It starts concretely from today with the first BioNTech-Pfizer vaccines produced on the Delpharm site in Saint-Rémy-sur-Avre” north of Paris, specifies Macron on Twitter. “250 million doses of Covid-19 vaccines manufactured in France in 2021: this is our goal,” he added.
250 million doses of Covid-19 vaccines created in France in 2021: this is our goal.
It begins today with the first BioNTech-Pfizer vaccines produced on the Delpharm site in Saint-Rémy-sur-Avre: bravo to all the teams!– Emmanuel Macron (@EmmanuelMacron) April 7, 2021
The vaccines were manufactured at BioNTech’s plant in Germany and were delivered to France on Tuesday for packaging and distribution.
They are not intended only for France, Delpharm having told UKTN that the country would receive its share of doses allocated between EU states, set at around 15%.
Employees at the Delpharm plant in Saint-Rémy-sur-Avre said production had increased in recent months, with the company employing around 60 more people at the site, a welcome development in the northern French city.
Another company will start depositing Moderna vaccines in central France in a few days, with Johnson & Johnson and CureVac vaccines to follow shortly thereafter.
The French authorities have been criticized for the slow deployment of the vaccine in the country, 14.2% of French people having received one or more doses, against 60.1% of the British.
(UKTN with UKTN)
.
